Regulatory B cells (Bregs) have an anti-inflammatory role and can suppress autoimmunity, by employing both cytokine secretion and cell-contact mediated mechanisms. Numerous Breg subsets have been described and have overlapping phenotypes in terms of their immune expression markers or cytokine production. A hallmark feature of Bregs is the secretion of IL-10, although IL-35 and TGFβ−producing B cells have also been identified. To date, few reports have identified an impaired frequency or function of Bregs in individuals with type 1 diabetes; thus our understanding of the role played by these Breg subsets in the pathogenesis of this condition is limited. In this review we will focus on how regulatory B cells are altered in the development of type 1 diabetes, highlighting both frequency and function and discuss both human and animal studies.

调节性 B 细胞 (Bregs) 具有抗炎作用，并且可以通过使用细胞因子分泌和细胞接触介导机制来抑制自身免疫。已经描述了许多 Breg 亚群，并且在它们的免疫表达标记或细胞因子产生方面具有重叠的表型。Bregs 的一个标志性特征是分泌 IL-10，尽管也已鉴定出产生 IL-35 和 TGFβ 的 B 细胞。迄今为止，很少有报告发现 1 型糖尿病患者的 Bregs 频率或功能受损。因此，我们对这些 Breg 亚群在这种疾病的发病机制中所起的作用的理解是有限的。在这篇综述中，我们将重点关注调节性 B 细胞如何在 1 型糖尿病的发展过程中发生改变，强调频率和功能，并讨论人类和动物研究。